ANNUAL REVIEW

2023

TRI

TRANSLATIONAL RESEARCH INSTITUTE

AUSTRALIA

• Artwork concept and narrative developed by David Williams. David is a proud Wakka Wakka artist at Gilimbaa.

TRI's Reconciliation Action Plan

The TRI community came together during National Reconciliation Week in May 2023 for the formal endorsement of TRI's inaugural REFLECT RAP 2023-2024 by Reconciliation Australia.

Endorsement marked an important milestone in our reconciliation journey and provided an opportunity to acknowledge the contributions of our cross-partner *One*TRI RAP Working Group, who embraced the process.

We acknowledge the valuable input of Tagai Management Consultants' Murray Saylor, and Elders Aunty Beryl Meiklejohn and Uncle Charles Passi, who contributed great insight to our early planning and kept the process moving.

Contributions from our *One*TRI community came from Professor Scott Bell, Professor Paul Clarke, Dr Natasha Jansz, Samantha MacDonald, Associate Professor Shivashanker (Shiv) Nagaraj, Jennifer Skinner, Charlotte Vivian, Rahm Rallah, Karen Murphy, Melissa Watter and our RAP champions Kirsten Kiel-Chisholm and Ryan Galea.

Culturally-led and informed research

"Let their voices guide us and connect us to a healthier future."

This artwork tells the story of TRI's reconciliation journey. A story that started with collaboration. A story built on the strength of its relationships. A story whose future depends on connection.

The connections are not only between the Indigenous and non-Indigenous voices working together within TRI, but between the traditional knowledge and contemporary technology that lies at the heart of its work. When these are combined, culturally-led and informed research enriches and strengthens its story.

Only by meaningful words and brave actions can TRI inspire and challenge others while transforming its own path, making sure the connections it builds keep this story on course.

Through this spirit of connection and collaboration, First Nations voices are embedded throughout TRI, allowing culture to be celebrated, stories to be shared, and a better future to be had by all.



Black and white voices in collaboration



Reconciliation goals: partnerships, collaboration, excellence and relationships.

Knowledge

TRI
TRANSLATIONAL RESEARCH INSTITUTE
AUSTRALIA

CONTENTS

Acknowledgement of Country

We acknowledge the traditional custodians of the land we are on, and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and future.

INTRODUCING **TRI**

Australia's Translational Research Institute (TRI) is one of the nation's youngest medical research institutes, having opened in late 2012.

TRI was constructed with a $356 million investment from the Queensland and Australian Governments, The Atlantic Philanthropies, Queensland University of Technology (QUT) and The University of Queensland (UQ).

Today it successfully operates as a unique collaboration between four major partners: UQ, QUT, Queensland Health and Mater Research.

The company Translational Research Institute Pty Ltd (known as TRI Corporate), in its capacity as trustee of the Translational Research Institute Trust, employs staff to manage and support the Institute's operations and advance its strategic goals.

OUR PURPOSE
TRANSFORMING HEALTH THROUGH COLLABORATIVE RESEARCH.

OUR VISION
EXCEPTIONAL SCIENCE, HEALTHIER LIVES.

OUR GOALS
PARTNERSHIPS, COLLABORATION, EXCELLENCE, RELATIONSHIPS.

A message from the **TRI BOARD CHAIR**

Emeritus Professor David Siddle

These past 12 months have been a time of remarkable progress and transformation for the Translational Research Institute as we mature into a second decade of operations and progress our commitment to build new translational manufacturing capability for Australia.

For the Directors of TRI, complex negotiations were required to resolve the pervasive issue of rising construction costs, along with the discovery of significant asbestos contamination across the TM@TRI construction site. To navigate a funding shortfall, the Board held discussions with TRI shareholders and the Queensland Government, leading to a resolution that would allow this important and significant development to progress. Contributions from TRI, The University of Queensland, Queensland Health and the Department of State Development and Infrastructure, delivered the additional resources to allow the project to proceed.

Early site works were substantially complete by the end of 2023 and TM@TRI now moves to main works construction. My fellow Directors and I congratulate the Queensland Government, Premier Steven Miles and Deputy Premier and Treasurer Cameron Dick for the vision and resolve shown to navigate a way forward for the TM@TRI project that is important for the development of Queensland's life sciences sector.

The COVID pandemic-fueled mRNA vaccine development that built on existing knowledge of monoclonal antibodies has combined with a massive increase in effort in the area of cell and gene therapy. This is creating vibrant and economically-important ecosystems in many parts of the world – most notably in the USA and in China.

TRI, as a key pillar of Brisbane's knowledge corridor and significant contributor within the Boggo Road Innovation Precinct, is involved in collective efforts to create a thriving local ecosystem of talent and global connections across health, biomedical and environmental sciences.

The TM@TRI project will carry many benefits for TRI and for Queensland. Our focus in the last half of 2023 has been on refinement of a fit-for-purpose operating model, suitable for the start-ups we aim to attract.

Already, the Translational Science Hub collaboration between global pharmaceutical giant Sanofi, The University of Queensland, Griffith University and the Queensland Government will be an important anchor tenant. We now have a strong pipeline of industry interest in both TM and TRI that augurs well for the future of biomedical manufacturing.

The complex planning and negotiation needed to make TM@TRI a reality required the talents of many. The Board congratulates Professor Bell and his Executive Leadership Team, along with Stuart Pickering, the Executive Project Director for TM@TRI construction and the work of other specialist consultants.

It is fair to say the complex economic and labour challenges fueling operating costs are an ongoing source of pressure for TRI and for our partners. We continue our work to address remuneration and capacity issues for TRI while creating a flexible and supportive workplace to attract and retain skilled professionals.

The Board and Management continue to seek alternative sources of revenue and funding that may further support the clinical innovation and research excellence that is occurring within the TRI community. To that end, we will explore opportunities within the $15 billion National Reconstruction Authority Fund that has identified medical science research and manufacturing as a priority area.

On a sombre note, we joined the international outpouring of sorrow over the loss of philanthropist Chuck Feeney who, through The Atlantic Philanthropies, gifted $50 million toward the establishment of TRI. At the time, it represented the largest sum from a non-government source to a single Australian medical research institute.

I was fortunate to have met Chuck and his wife Helga on several occasions and their dedication to philanthropy and strong belief in the benefits of translational research and development serves as inspiration to all.

In conclusion, I wish to sincerely thank the Directors of TRI Pty Ltd for their commitment and dedication to the governance of the organisation.

Emeritus Professor David Siddle, BA (Hons) PhD, FASSA

Board Chair, Translational Research Institute

SIGNIFICANT PROGRESS MADE ACROSS ALL FOUR KEY FOCUS AREAS OF THE TRI BOARD-ENDORSED 2022-2024 STRATEGIC PLAN, WHICH AIMS TO:

- **Promote thriving research, clinical and industry partnerships;**
- **Foster a collaborative environment for people and ideas to flourish;**
- **Achieve research excellence through access to world class capabilities, and;**
- **Strengthen relationships for investment in ideas, discovery and outcomes.**

CEO UPDATE

Professor Scott Bell

Chief Executive Officer TRI

This past year, we have successfully met, and in many cases exceeded, the Strategic Plan objectives we set back in 2022 across the areas of Partnerships, Collaboration, Excellence and Relationships.

WITH THE HELP OF TRI PARTNERS, THIS YEAR WE ALSO CREATED A NEXT DECADE VISION TO AFFIRM OUR PRIORITIES OUT TO 2032 WHICH INCLUDE:

- **connecting with clinic;**
- **supporting excellence in discovery platforms;**
- **developing and manufacturing novel diagnostics and therapeutics;**
- **and, growth in clinical trials and industry across the TRI community.**

This work will be underpinned by our unique environment that advances discovery and translation; our inclusive culture; our enablers that support research translation; and the impressive expertise within TRI.

I am indebted to our Shared Leadership Group for their active engagement in helping us enliven a *One*TRI culture and create an environment of collaboration, reward and recognition, that is important to our community. Our inaugural *One*TRI Conference in October was a 2023 highlight with more than 300 attending, 39 speakers, 24 panelists and 14 poster presentations. The conference showcased the translational research conducted at TRI, facilitated networking between academics, researchers, clinicians and industry experts, and featured presentations focusing on careers, EMCRs, collaboration and cutting-edge capabilities.

The deliberate focus we're placing on EMCRs has also led to a raft of new professional development opportunities. Representatives from all partners are now highly engaged in creating a meaningful development program for their peers including through our Research Translation Committee seminar series.

Similarly, our Respect at Work committee advanced engagement on important issues like Sexual Harassment Awareness and Prevention, including Ethical Bystander training, setting the standards for a truly safe, inclusive and diverse TRI community. We've also focussed on Wellbeing at TRI, protecting our most important asset - our people - and are recognised as a Skilled Workplace by Mental Health First Aid Australia. I thank all members of our RAP Working Group, particularly Elder Aunty Beryl Meiklejohn for her wise counsel, as we continued to progress our REFLECT objectives during 2023.

An outstanding body of work has been delivered across the past 12 months in Research and Clinical Engagement to upskill TRI's research community and drive collaborations and translation. Our TRI Grant Scheme Administration continues to bear fruit with seven new project grants through our 2023 Linc Showcase and 21 in total being administered. TRI and the Queensland Department of Education SPARQ-ed collaboration continues to thrive with over 2500 students' part of the program in 2023. The Translation Pathways program upskilled 48 EMCRs, with four being awarded a Translation Fellowship. Program alumni have now raised more than $14 million in funding. Consumer engagement has also been a priority with workshops for researchers, grant and document reviews, group tours.

TRI's Translational Trials team was supporting 29 studies by the end of 2023 across disease areas ranging from dermatology to oncology. Eight new studies opened at our TRI Children's facility at Queensland Children's Hospital, and another 100 are ongoing. Our PA-based Clinical Research Facility had 32 new studies opened in 2023, 123 open overall and it supported 57 industry partners.

A strong commitment to data-driven decision-making in our Core Facilities led to substantial progress in the development of automated reporting to enable greater efficiency. We also worked closely in collaboration with UQ to address significant challenges in staff of our Biological Research Facility. Our research capability was further enhanced with the installation of a cutting-edge multiphoton and super-resolution microscope.

We are now full steam ahead on our Translational Manufacturing facility which is on track for a late 2025 building handover, with Built and Savills driving construction. I would like to acknowledge the incredible support we continue to receive from members of our Industry Advisory Group which has been instrumental in ensuring TM's facilities and operations remain fit for purpose for end users.

TRI continues to play a pivotal role in working alongside all levels of government to promote Brisbane's evolving knowledge corridor and specifically our place at the heart of the Boggo Road Innovation Precinct. For example, Ausbiotech attracted international delegates to Brisbane, giving us an opportunity to showcase TRI and TM@TRI capabilities and our partners' research excellence. We welcomed over 80 delegates to tour TRI, our Clinical Trials Facility and Thermo Fisher.

In closing, I am sincerely grateful for the ongoing support of the members of my Executive Leadership Team, the TRI and TRI Foundation Boards, our partner shareholders – most importantly their research leaders and teams - and the industry and sector members who contribute to our dynamic TRI community.

Professor Scott Bell MBBS MD FRACP FThorSoc

CEO, Translational Research Institute

2023 HIGHLIGHTS

$42.9M+ in research grants

48 researcher awards

593 research publications

2,163 citations

425 publications in journals in the top quartile for its subject

17 in top 1%

publications mentioned in **600** news outlets in **46** countries

41 publications with an industry partner

340 publications with an international collaborator

(*publication metrics based on data accessed on April 3, 2024)

CONNECTING WITH THE CLINIC

Our community will collaborate with clinicians and consumers to address current clinical dilemmas by:

- Assembling patient cohorts
- Leveraging digital records and data expertise
- Establishing long-term biorepositories

DISCOVERY PLATFORMS

Our researchers will effectively apply technologies to gain novel insights into diseases, including:

- Genomics
- Multiomics
- Microbiome
- Bioinformatics
- Disease models

DEVELOPING AND MANUFACTURING DIAGNOSTICS AND THERAPEUTICS

Our community will build close relationships with industry to develop novel diagnostics, biomarkers and therapeutics and apply our research strengths by:

- Pre-clinical testing
- cGMP manufacturing
- Theranostics
- Biofabrication
- First-in-human testing

CLINICAL TRIAL INDUSTRY GROWTH

Our community will engage strongly with clinical trials and industry by supporting:

- Access to novel technologies and therapies
- The development and conduct of clinical trials
- Strong links between researchers and industry

OUR ENVIRONMENT

Our unique environment will advance discovery and translation advance

- Through opportunities for collaborations among our research, clinical and industry partners
- Supporting researchers to build knowledge, skills and capacity in research translation

OUR CULTURE

Our community will focus on:

- Promoting a culture of research excellence
- Developing our early-mid career researchers for future success
- Supporting diversity and inclusion within our community including Aboriginal and Torres Strait Islander peoples

OUR ENABLERS

We will support research translation through:

- Clinician partnerships
- Consumer engagement and industry collaborations
- Constructing TM@TRI, for scale-up manufacturing
- Enhanced partnerships with centres of research excellence globally

OUR EXPERTISE

We will continue our:

- Focus on immunology of disease, cancer, chronic and severe diseases, neurosciences.
- Support for emerging research fields that are strategically important.

2023-2033 next decade focus

With TRI rounding off our first decade and looking ahead to our 20-year milestone, coinciding with a global focus on Brisbane for the 2032 Olympic Games, TRI has developed a 10-year strategic focus.

The TRI Shared Leadership Committee identified focus areas for 2023-2033, incorporating connected clinical research; discovery platforms that leverage omics, bioinformatics and disease models; development and manufacturing of diagnostics, biomarkers and therapeutics; and clinical trials to advance novel therapies and personalised medicine.

At its core is the creation of a unique ecosystem and culture that is already enabling collaboration and combining expertise with facilities – with the goal of securing TRI's position as a world-class institute.

TRI will continue to focus on chronic and severe disease, cancer, immunology and neuroscience.

Underpinning the research will be opportunities for training in translational methods; building partnerships with industry and clinicians; supporting early-career scientists; and ensuring a diverse, inclusive and connected community.

2023 Highlights /

Translational Manufacturing@TRI

Bulk excavation neared completion in late 2023, as work on the TM@TRI site moved towards foundation work – a major step in the construction of Australia's first scale-up biomedical manufacturing facility for early-phase start-up biotech companies.

Opening in early 2026, TM@TRI will enable the companies to establish, build, test and develop their products.

The $100 million facility will position TRI as an Australian leader in the space, attracting a range of industry from local start-ups and SMEs to international biomedical companies. It will give local start-ups the option of staying here. Up to 15 per cent of start-ups move interstate or overseas to expand or manufacture.

TM@TRI will create 500 highly skilled jobs in the next decade, with an additional 50 workers to be trained each year in cGMP manufacturing processes.

TM@TRI is proudly funded by the Queensland Government and TRI.

Cost benefit ratio: $1 invested in TM@TRI returns $1.51 in economic benefit back to Australians.

Shovel Ready: early construction works underway for early 2026 opening.

200 jobs will be created: 1500 construction and 500 highly skilled/STEM roles.

TM@TRI will be the only facility where companies can perform their own product manufacturing in regulatory compliant cleanrooms.

TM@TRI will enable TRI to expand the open access to current Good Manufacturing Practice (cGMP) training, upskilling Australia's workforce in the methods, facilities and controls used in manufacturing.

Welcome to the

Translational Science Hub

The Translational Science Hub has become a TRI tenant in 2023, bringing together global pharmaceutical leader Sanofi, UQ, Griffith University and the Queensland Government.

TSH is creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science, connects Queensland researchers with Sanofi scientists in France and the US.

Having both Sanofi and the TSH at TRI gives researchers access to expertise and insights in biomedical innovation, product development and commercialisation.

Pictured Above - Left to Right: **Griffith University VC Professor Carolyn Evans, UQ VC Professor Deborah Terry, Sanofi Global Head of Vaccine R&D Dr Jean-Francois Toussaint, Premier Annastacia Palaszczuk, Deputy Premier and Minister for State Development Steven Miles, Minister for Science Meaghan Scanlon.**

Awards and Appointments

High-profile awards and appointments are an indicator of the standing of TRI-based researchers in their fields, demonstrating their reputations, the high regard for their work and the credibility of their achievements.

Pictured Above; **Professor Di Yu (UQ).**

Professor Di Yu: national recognition for outstanding contributions

UQ Professor Di Yu has been elected a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS), in recognition of his outstanding achievements and exceptional clinical, leadership, industry and research contributions.

Professor Yu is a Chair in Paediatric Immunotherapy, Professor of Immunology, Director of Ian Frazer Centre of Children's Immunotherapy Research and Head of the Systems and Translational T-cell Immunology Laboratory.

By investigating T cells, he has been able to develop an innovative "systems immunology" approach to monitor a person's immune system and design new strategies to treat autoimmune diseases, infection and cancer.

Professor Yu was the AAHMS 2021 Jian Zhou Medal winner, singling him out as a rising star of Australian health and medical science, and recognising a significant impact in translational medical science.

He subsequently became an Associate Member, before being elected a Fellow in 2023.

With Professor Yu's election as a Fellow, UQ immunology researcher Associate Professor Fernando Guimaraes has become a new AAHMS Associate Member.

Success at a glance

Professor Di Yu also being awarded the Australian Academy of Science's Jacques Miller Medal, recognising research of the highest standing in the field of experimental biomedicine.

UQ Professor Peter Soyer receiving the highest honour from the Australasian College of Dermatologists, the 2023 Silver Medal, for distinguished service to dermatology. He is focused on revolutionising early melanoma detection using 3D body imaging systems that take an image in milliseconds.

QUT Professor Gene Tyson receiving a $3.3million Australian Research Council Australian Laureate Fellowship, recognising an outstanding researcher of international reputation and enabling use of meta-omic technologies, advanced bioinformatic tools developed by his team and machine learning for a detailed exploration of the human gut microbiome.

TRI CEO Professor Scott Bell being named, through his UQ affiliation, the Pulmonology Field Leader in The Australian's Research 2024 list, identifying 250 of the nation's top researchers.

Associate Professor Sumaira Hasnain from Mater Research receiving the inaugural Lawrie Powell AC Grant Award from The Gastroenterological Society of Australia, recognising outstanding achievements and services in hepatology.

2023 Highlights /

Discovery Successes

Scientific discovery flowing from research conducted at TRI ensures progress along the translational pipeline towards better and more personalised treatments, targeted therapeutics and cutting-edge medical devices. Scientific discoveries and successes in securing competitive national funding have been achieved in 2023 in health priority areas including arthritis and cancer, and in emerging fields such as gut health.



Rheumatoid arthritis breakthrough the first of its kind

The world's first-in-human trial for rheumatoid arthritis has tested a novel immunotherapy and found that half of the 17 people involved were in remission eight weeks later.

TRI-based Professor Ranjeny Thomas from UQ led the trial at the Princess Alexandra Hospital, as part of a collaboration with pharmaceutical giant Janssen.

Rheumatoid arthritis occurs when the body mistakes its own proteins within joint tissue as foreign, resulting in an immune response.

The clinical trial provides evidence that the immunotherapy was well tolerated, that it modifies the immune response, and that it appears to have a broader beneficial effect on the rheumatoid immune response.

While a product for treatment of rheumatoid arthritis is still years away, this trial now opens the door to exciting trials to look at potential for long-term disease control and prevention in people at risk.

Success at a glance

UQ Associate Professor Helmut Schaider partnering with the Queensland Emory Drug Discovery Initiative to identify a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients - opening the potential for drug development.

The TRI-based Australasian Kidney Trials Network collaborating with researchers from three states, including from UQ, on a clinical trial that found a simple change to intravenous fluids could deliver real benefits for kidney transplant recipients and reduce their need for dialysis by 25 per cent.

QUT Professor Jyotsna Batra leading a study that analysed genetic data to find that past liver disease can play a role in severe COVID-19 infection.

Pictured Top; **Associate Professor Helmut Schaider (UQ).**
Bottom; **Professor Jyotsna Batra (QUT).**
Left Page; **Professor Ranjeny Thomas (UQ).**

Significant Funding

TRI-based researchers from UQ and Mater Research sharing in more than $12million in National Health and Medical Research Council funding, supporting projects in cancer, autoimmune diseases, tuberculosis, osteoporosis and paediatric non-alcoholic fatty liver disease.

Medical Research Future Fund support for UQ Associate Professor Fernando Guimaraes, awarded $990,020.97 for a study to personalise immunotherapy for better cancer treatment outcomes.

Associate Professor Fernando Guimaraes (UQ).

The Australian Research Council (ARC) providing support to QUT's Professor Phil Pope and Dr Luis Coelho through its Future Fellowship scheme, with a combined $2 million for research into small proteins and the microbiome.

Mater Research Professor David Hume and Associate Professor Katharine Irvine securing ARC Discovery Project support, with $875,054 to study innate immune cells and build a holistic view of postnatal development.

Professor Gene Tyson and Associate Professor Simon McIlroy from QUT leading a successful bid for an ARC Discovery Project grant, with $499,391 to study how genetic material is exchanged between microorganisms, and how this helps them adapt to our rapidly changing environment.

QUT Associate Professor Ben Woodcroft integrating microbial community and climate data using $374,079 in support from an ARC Discovery Project grant.

Dr Andrew Brooks from UQ securing an Australia's Economic Accelerator Seed Grant, with $307,524 to progress work in creating new cell-based cancer immunotherapies.

International Standing

Global recognition opens doors for TRI-based researchers to advance scientific discovery, collaborate with the best minds, share their knowledge and position Australia as a leader in their fields of endeavour.



Pictured Above; **Professor Gene Tyson (QUT).**

Professor Gene Tyson: international leadership role in microbiology

QUT Professor Gene Tyson has been elected to the American Academy of Microbiology, recognising excellence, originality, service and leadership in the field.

He was the only Australian to be elected to the American Society for Microbiology's honorific leadership group in 2023.

The group provides leadership to one of the largest life science societies in the world and is tasked with contributing microbiological expertise in the service of science and the public.

Professor Tyson is the Director of QUT's Centre for Microbiome Research and co-founder of TRI-based biotech company Microba.

Pioneering work from Professor Tyson's research group has driven gut health discoveries, understanding of metabolic processes, and development of widely-used bioinformatic tools for analysing genomic data.

Global Achievements

Professor Tyson, QUT Associate Professor Ben Woodcroft and UQ Emeritus Professor Michael Roberts being named highly cited researchers. Each authored multiple highly cited papers which rank in the top 1 per cent by citations for their fields, placing them among only 7,125 researchers to be named on the list in 2023.

TRI hosting the International Conference on Bioinformatics in November, with a four-day program of research presentations, plenary sessions, poster sessions, workshops, software demonstrations and panel discussions.

UQ's Dr Yousuf Mohammed working with the United States Food and Drug Administration (FDA) to develop regulatory guidelines for products such as lotions, creams and gels, with two grants to better understand why topical drug products fail.

BostonGene Corporation in the United States announcing a major research collaboration with Dr Joshua Tobin from Mater Research, to ultimately improve treatment for patients in advanced stages of follicular lymphoma.

A collaboration between Mater Research Dr Yuanhao Yang and Professor Jake Gratten and researchers from Denmark, the United States and around Australia to identify a genetic link between platelets and Parkinson's disease, with findings published in international journal Cell Genomics.

Mater Research Professor Josephine Forbes supervising a study using tissue samples sources from the University of Florida and collaborating with researchers from the University of Tennessee and the University of Miami – ultimately finding evidence of changes to the pancreas in people with Type 1 diabetes.

Mater Research Executive Director Professor Maher Gandhi and PhD candidate Muhammed B Sabdia securing one of only two Single Cell Grants in Australia from global life sciences company Parse Biosciences, recognising the merit and feasibility of their research. The grant will enable single cell sequencing of specific T-cells from patients with Chronic Lymphocytic Leukaemia. The aim is to pave the way for novel immunotherapies to improve outcomes for patients with inferior survival rates.

Pictured Top of Page; **Professor Josephine Forbes (Mater Research).**
Bottom; **Muhammed B Sabdia and Professor Maher Gandhi (Mater Research).**

TRI is integral to a Queensland innovation sector with integrated life sciences capability, fostering an ecosystem of talent and global connections across academia, industry, healthcare and the community.

OUR **ECOSYSTEM**

The ecosystem we are shaping gives us critical mass, research strengths, clinical synergies and commercialisation expertise, and enables us to drive important collaborations.

It enables world-class medical research and supports early-phase biotech companies to focus on driving scientific excellence and innovation for complex global health problems.

We are part of **Brisbane's knowledge corridor**, running north to south through Brisbane's inner city, featuring clusters of knowledge-based businesses, universities, research institutes and hospitals.

Uniquely connected and offering a full suite of life sciences service, it is one of the largest hospital and healthcare clusters in the southern hemisphere and represents Queensland's largest collection of knowledge-intensive industries.

The corridor includes four quaternary hospitals, three tertiary hospitals, three universities and a multitude of specialist research institutions as well as industry and the community. The integration enables to enhanced evidence-based healthcare design and delivery.

TRI is an anchor institution within the **Boggo Road Innovation Precinct**, focused on health, science, innovation and education and situated within a 5km radius of the CBD.

We are co-located in the precinct with the Ecosciences Precinct, Princess Alexandra Hospital, The University of Queensland, Queensland University of Technology, Patheon by Thermo Fisher Scientific and the Pharmacy Australia Centre of Excellence.

The precinct provides a collaborative environment for scientists, innovators, entrepreneurs and professionals with global connections across health, biomedical and environmental sciences.

Precinct strengths are in key translational and healthcare service capabilities, such as clinical sciences and imaging; commercial, advanced and clinical cGMP manufacturing; virtual and augmented reality; data visualisation; biotechnology; immunology; and vaccine and therapeutic drug development.

In recognition of the growth of our biotechnology precinct, The University of Queensland has cemented its presence and announced in 2023 a fourth campus, **UQ Dutton Park**.

The Dutton Park campus underscores UQ's commitment to partnering with TRI-based researchers, including colleagues from Mater Research, and other biotech facilities to maximise opportunities to secure Queensland's position as a global research and innovation hub.

UQ Dutton Park is the primary teaching and research location for the School of Pharmacy, which has been located at the site for more than a decade.

The campus houses the Queensland Alliance for Environmental Health Sciences, an auditorium and other teaching spaces, laboratories, a UQ library branch, specialised training rooms and UQ Healthcare's Cornwall Street clinic, which has recently become a Medicare Urgent Care Clinic.

UQ has almost 300 staff at the precinct and around 700 undergraduate and postgraduate students.

TRI is co-located with the Princess Alexandra Hospital, adjoins Thermo Fisher Scientific, and is home to researchers from academia and industry, research support services and peak bodies.

This enables us to collaborate on initiatives that build on research excellence to deliver clinical translation, entrepreneurial enterprise and biomedical manufacturing capability.

Our Ecosystem /

Collaborators, Partners and TRI-based Industry

We are part of the **BioManufacturing Alliance (BMA**) with The University of Queensland, QIMR Berghofer Medical Research Institute, Life Sciences Queensland, Patheon by Thermo Fisher Scientific, Cytiva and Springfield City Group.

The alliance brings together capabilities across biotherapeutics and vaccines to develop biomanufacturing capability and self-sufficiency, establish an integrated precinct delivering life-saving therapies, underpin workforce training and create sustainable, high-value jobs.

Our **industry tenants** include AdvanCell, EMVision, Infensa Bioscience, Microba, Microbio, Ocugene, Oroborus and Vaxxas.

TRI's model aims to bolster the startups in their pre-revenue phase, with access to laboratories, GMP compliant cleanrooms, core facilities, critical systems monitoring and specialist expertise.

TRI facilitates access to other entities including venture capital firms, specialty laboratory services, peak bodies and National Collaborative Research Infrastructure Strategy (NCRIS) entities that enable access to equipment and expertise.

Among the entities housed at TRI are 360biolabs, Brandon Capital, Health Translation Queensland, MTPConnect, the National Imaging Facility and Therapeutic Innovation Australia.

TRI is home to a Queensland peak body that offers opportunities for industry stakeholders to come together and cooperate to grow their businesses and support the creation of a dynamic, internationally competitive and sustainable life sciences industry.

Life Sciences Queensland Limited is central to shaping the strategic direction of the industry in Queensland and influence public policy.

LSQ also provides members with tools, services, market intelligence and access to an international network of life sciences organisations, with the aim of identifying business opportunities and accelerating growth.

Pictured Left:
Professor Philip Hugenholtz (Microba Life Sciences).

COMPANIES AT TRI

Microbio
MICROBA
vaxxas
Vale Life Sciences
Ocugene
EMVISION
infensa BIOSCIENCE
Oroborus
AdvanCell

BIOTECH SECTOR SERVICE PROVIDERS AT TRI

MTPConnect
THERAPEUTIC INNOVATION AUSTRALIA
BRANDON CAPITAL
National Imaging Facility
360biolabs
Health Translation Queensland

TRI Core Facilities:

Microsopy
Generating high-quality reproducible images and providing expertise in experimental design, equipment selection and downstream data analysis.

Flow Cytometry
Widely used and versatile technology for studying the characteristics and biological functions of cells.

Histology
An essential fundamental technique for better visualising and understanding the microanatomy of cells and tissue.

Proteomics
Using mass spectrometry to identify, quantify and characterise large numbers of proteins from samples to gain insights into biological function and changes within cells and tissues.

Pre-Clinical Imaging
Providing access to clinically relevant technologies that mirror those available in healthcare.

Biological Research Facilities
Providing high-quality research support during preclinical phases to advance human treatments and therapies.

Gnotobiotics
The only facility of its kind in Queensland, providing highly specialised and sought-after gnotobiotic and germ-free capabilities, with application in cancer research, allergy, autoimmunity and gastrointestinal disorders.

Our Ecosystem /

World-class facilities at TRI

More than $24.3 million has been invested in core facilities equipment and 43 staff members are available to support internal and external researchers and institutions.

We bolster researchers and biotech startups through access to TRI Core Facilities, with world-class, emerging technologies, equipment and support across flow cytometry, microscopy, histology, proteomics, preclinical imaging, biological research facilities and gnotobiotics.

Bone, brain, bacteria and blood cells in Brisbane-first microscope's sights

The TRI Microscopy Facility has installed the only Zeiss LSM 980 intra-vital microscope of its kind in Brisbane, paving the way for researchers to see deeper into various 3D tissue samples.

The microscope incorporates a state-of-the-art multi-photon laser, spectral detector and super-resolution module, adding several new technology capabilities to the facility, enabling imaging of overlapping fluorescence spectra as well as cells and tissue sections with resolution down to 90nm.

The use of Infra-red laser excitation also permits light to penetrate deeper than conventional microscopy, granting researchers a new depth of understanding within their tissue models.

Such capability bridges a gap between routine light microscopy and pre-clinical imaging already available at TRI.

TRI Senior Microscopy Scientist Mark Scott says the microscope can be used for studying a range of sample types including bone, bone marrow, brain and other organs.

Custom objective lenses allow optically cleared samples to be imaged to even greater depth, as well as imaging of organoids – 3D miniature versions of organs that mimic their behaviour that will improve our understanding of disease progression and our drug screening capabilities.

UQ PhD candidate Rachel Rollo has used the Airyscan 2 super-resolution module of the Zeiss LSM 980 to investigate bacteria Mycobacterium bovis and Mycobacterium tuberculosis – the latter being responsible for tuberculosis in humans.

Pictured Above:
Mark Scott, Senior Microscopy Scientist (TRI).
Left:: **Rachel Rollo (UQ).**

Another Major Achievement in TRI's Facilities

Negotiations have been held with the national regulator, equipment has been mobilised and TRI space has been reconfigured to enable SARS-CoV-2 research to be conducted in PC3 facilities. A closedown in April 2023 enabled the reconfiguration so that the space can accommodate both SARS-CoV-2 research and the mycobacterium tuberculosis research that has historically been conducted there. A new sub-committee of the Shared Operations Committee will oversee the coordination, planning and work to be undertaken.

From Innovative Research to Clinical Practice

TRI's mission is to improve the translation of innovative research into clinical practice. TRI provides expertise, world-class research facilities and connections to clinicians and clinical trial facilities. Our Clinical and Research Translation business unit enhances the collaboration, running two purpose built and fully staffed clinical research facilities and providing a Translational Trials support team.

Pictured Above:: **Dr Michael Wagels (ACCISS).**

Collaboration results in world first with successful nerve repair surgery

World-first sutureless nerve repair surgery has been performed at the Princess Alexandra Hospital (PAH), with the TRI Translational Trials team providing vital support.

The surgery was part of a COAPTIUM Connect System Australian trial, involving the TRI Translational Trials team, the Australian Centre for Complex Integrated Surgical Solutions (ACCISS), medical technology company TISSIUM and procedures at both the PAH and Gold Coast University Hospital.

PAH plastic and reconstructive surgeon Dr Michael Wagels performed the first surgery, saying the technology enables repair without the use of sutures which can negatively impact the nerve.

"Removing the need for sutures allows better regeneration of the nerve, benefiting the patient long term," Dr Wagels says.

The first patient was enrolled as part of a peripheral nerve repair study in Australia. The COAPTIUM Connect System Australian trial is ongoing.

ACCISS was established in 2019 as a multidisciplinary department that helps clinical teams better understand and solve complex medical challenges, as well as supporting patient education and the training of junior medical, nursing and health professionals, using new and emerging technologies.

Since then, it has delivered hundreds of medical devices and facilitated a series of groundbreaking procedures: successfully implanting a 3D-printed bone scaffold in a man's leg to avoid amputation and a 3D-printed skull piece after a horrific motorcycle accident.

In 2023, the ACCISS team reconstructed a new oesophagus for Brisbane man Jason Jones. After choking on a meal and passing out, an urgent endoscopy was performed and Mr Jones was found to have Stage 3 oesophageal cancer. The new oesophagus enables him to eat and breathe normally.

More Clinical Support Programs

TRI funding Director of Imaging Technology Professor Graham Galloway, enabling a focus on novel breast cancer imaging technologies and use of advanced MRI technologies for clinical disorders including psychiatry, neurology, brain injury and trauma. Professor Galloway is also the academic lead for the TRI Preclinical Imaging facility, providing mentoring and strategic advice as well as engaging clinicians and encouraging translation.

TRI contributing to the funding for microbiome research under the leadership of Professor Mark Morrison. As the UQ Chair, Microbial Biology and Metagenomics, Professor Morrison has worked closely with staff from the Germ Free and Gnotobiotic facility and other TRI-based scientists in advancing their capability for microbiome-based manipulations of preclinical models. His team preserves tissue biopsies collected in the clinic, now being used in studies involving TRI-based, national and international clinician scientists working in inflammatory bowel disease and disorders of gut-brain interactions.

3D total body imaging for early skin cancer detection

A sophisticated 3D imaging system fitted with more than 90 cameras has been installed at the TRI Clinical Research Facility, representing the latest line of defence in helping with early identification of skin cancers.

The imaging system is part of the UQ-led ACRF Australian Centre of Excellence in Melanoma Imaging & Diagnosis, with support from a $10 million infrastructure grant from the Australian Cancer Research Foundation. TRI is also providing support for the project.

Called Vectra, the imaging system relies on 92 cameras to take a photo at once which, when combined, generate a 3D total body avatar capturing nearly the entire skin surface.

Lead investigator, TRI-based UQ researcher Professor H Peter Soyer, says the technology significantly improves the tracking of spots and moles over time.

It is being used for a clinical trial in skin cancer, with a target of attracting 15,000 participants.

Pictured: **Professor H Peter Soyer (UQ),**

Specialist facilities opening doors to paediatric research

TRI facilities adjoining the Queensland Children's Hospital have underpinned clinical research into diabetes, foetal alcohol spectrum disorder and premature births.

TRIC is TRI's clinical research facility at the Centre for Children's Health Research, opening doors for children and their parents, offering a welcoming environment for participating in leading-edge research into healthcare improvement and life-saving treatments.

- UQ researchers have used TRIC in the first study of its kind to report on outcomes in children with fetal alcohol spectrum disorder (FASD). TRIC experts collected clinical samples and measurements, including saliva, cheek swabs, urine, blood pressure and heart rate, from children aged four to 15 years.

- QUT and Menzies School of Health Research have been using TRIC to study early-onset pneumonia in children. The PneuMatters study is investigating whether vaccinating pregnant First Nation mothers reduces acute lower respiratory infections in their infants. Pregnant mothers join the study for 12 months, visiting TRIC clinic rooms three times for sample collection. Researchers then use the adjoining TRIC laboratory to process the samples.

- A major national research initiative has used TRIC in a bid to find the causes of – and prevention for – type 1 diabetes. Children's Health Queensland has recruited 1500 babies from around Australia who have a close relative with type 1 diabetes, such as a parent or sibling. Researchers will use TRIC facilities to investigate environmental factors that may contribute to the development of type 1 diabetes in children.

Pictured: **Centre for Children's Health Research.**

More major steps in translating research into the clinic

- **QUT's Australian Translational Genomics Centre (ATCG), led by TRI-based Associate Professor Paul Leo, is part of the Omico Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program.** It has secured more than $185million, with an estimated $12million to come to the ATGC, to provide free genomic profiling to 23,000 Australians with advanced or incurable cancers and identify potential matches for patients to clinical trials with new targeted therapies.

- **The ATGC was also designated as the lead site in Queensland for the Omico TSO500 next gen sequencing Cancer Screening Program (CaSP).** Patients sequenced as part of CaSP will have their data uploaded to a Cancer Alliance Queensland database, linking the anonymised results to clinical data available for future research. The work has strong patient advocacy led by Australian Families 4 Genomics.

CONNECTING **RESEARCHERS**, **PARTNERS** & **COLLABORATORS**

Pictured Top, left to right: **The opening of the Vaxxas Biomedical Facility, with David McLachlan (Brisbane City Council) , Deputy Premier and Minister for State Development Dr Steven Miles, President and CEO David Hoey (Vaxxas) and Chairman Paul Kelly (Vaxxas and OneVentures).**

Above, left to right: **Dr Laverne Robilliard (Vaxxas), Paul Kelly, Dr Steven Miles, Chief Technology Officer Dr Angus Forster (Vaxxas).**

Supporting Industry

TRI supports start-up biomedical technology companies through access to specialist facilities and expertise, co-location with support services and clinicians from the adjoining Princess Alexandra Hospital, and a networked ecosystem that fosters collaboration and translation. Eight biotech tenants are supported to grow their capabilities, develop new products, conduct clinical research and build strategic new partnerships.

360 labs

Biotech sector service provider **360 labs** has experienced a growth phase, opening a new, expanded state-of-the-art laboratory and capabilities at TRI and leveraging co-location to develop a strategic partnership with global healthcare company Sanofi.

The speciality laboratory services organisation for therapeutic, vaccine and diagnostics development has expanded capacity to process time-sensitive samples, offer extended biomarker profiling and central lab services.

Laboratory space at TRI enables 360 labs to support large molecule, advanced modality and vaccine clinical trials under good clinical practice, good clinical laboratory practice and ISO/IEC 17025, enabling acceptance of data from globally regulatory bodies.

Their new laboratory and partnership enables Sanofi to be supported through end point analysis of early-stage clinical trials based in Queensland.

Vaxxas

Biotechnology company **Vaxxas** has opened a new 5,500sqm headquarters in Brisbane to scale up manufacturing of its needle-free vaccine patch platform, supporting up to 200 jobs.

Vaxxas has been working at TRI on the commercial application of technology developed at UQ to make vaccines more convenient with a high-density microarray patch. It is covered in thousands of tiny vaccine-coated microprojections that deliver the vaccine to abundant immune cells just below the skin's surface.

Other Vaxxas achievements include:

- **securing funding from a Federal Government Cooperative Research Centre Project, advancing development and clinical testing of the first COVID-19 vaccine delivered with the microarray patch.**
- **receiving $5.4 million from global charitable foundation Wellcome Trust to conduct initial studies and a Phase I clinical trial for a potential second-generation typhoid vaccine delivered with the microarray patch.**
- **reporting initial results from a Phase I clinical trial of the Vaxxas patch with COVID-19 vaccine, showing eight times the immune response and no adverse reactions.**
- **starting a Phase I clinical trial for influenza in Brisbane, Morayfield and on the Sunshine Coast.**

Breakthroughs and Milestones

Precision microbiome company **Microba Life Sciences** has celebrated successes in 2023, including:

- Launching testing product range MetaXplore to healthcare professionals under the brand Co-Biome.
- A distribution agreement with SYNLAB International enabling distribution of testing technology in Turkey and Czech Republic, following a December 2022 announcement of distribution for Italy and Portugal.
- Receiving formal ethics approval for their Phase I in human clinical trial of novel drug candidate MAP 315 for ulcerative colitis.

AdvanCell has become the first theranostics radiopharmaceutical start-up to be an industry tenant at TRI. AdvanCell is developing a scalable and deployable platform, using research infrastructure at TRI Preclinical Imaging and engaging with TRI-based researchers to identify new targets for radiopharmaceutical therapy.

Microbio has marked its first anniversary at TRI, growing significantly in staff numbers to support preclinical manufacture, ahead of anticipated pilot scale manufacturing here for their bloodstream infection and defence pathogen platforms. Microbio has gained clearance to sell its pathogen test to help identify sepsis in Europe, the UK and India – and is seeking clinical trial partners to deliver the diagnostic test worldwide.

Infensa Bioscience has been recognised for its expertise and research in cardiovascular disease, development of therapeutics to reduce mortality from heart attack and stroke, innovation and industry excellence. Achievements in 2023 include:

- Joining Brisbane Economic Development Agency's MedTech Global Accelerator program, enabling links with global partners for collaboration, investment and distribution deals.
- Chief Scientific Officer and UQ Professor Glenn King receiving the Prime Minister's Prize for Innovation, recognising his pioneering research into peptides from Australian funnel-web spider venom as potential human therapeutics.
- CEO Associate Professor Mark Smythe winning a Life Sciences Queensland GENE Award for Industry Excellence, recognising a major impact to the success of our life sciences industry.

Fostering Clinical Collaboration

Research has a major role in informing advances in healthcare, making collaboration between scientists and clinicians vital in translating discoveries in a laboratory into products, devices and services for treatment and patient care. TRI provides an ecosystem that encourages conversation, hosts events that facilitate knowledge sharing, and has initiatives that cement partnerships.

Grants to fast-track digital healthcare solutions

TRI and the Australian e-Health Research Centre at CSIRO have jointly awarded a total of $300,000 to research projects in cancer, diabetes and liver disease – each aimed at solving a healthcare challenge.

The grants were awarded to research teams which included a TRI-based researcher, CSIRO scientist and a TRI partner clinician from Metro South Health.

QUT's Professor Rik Thompson, CSIRO's Associate Professor Jason Dowling and MSH's Dr Thomas Lloyd are refining portable NMR technology to generate 3D images of mammographic tissue to assess its density and ultimately improve breast cancer outcomes.

Breast density phantoms have been custom-made from 3D-printed scaffolds and gels, and assessed at TRI, enabling analysis and generation of data that has been shared with CSIRO collaborators.

The work has resulted in a new collaborative project to identify the molecular and cellular basis of mammographic brightness and Dr Sandy Minck's recruitment as a consumer advocate for both projects.

Other TRI/CSIRO grant recipients include UQ's Professor Elizabeth Powell, CSIRO's Dr Sankalp Khanna and MSH's Dr Lucy Green, working to identify people with non-alcoholic fatty liver disease at increased risk of liver disease progression.

QUT's Eamonn McKenna, CSIRO's Dr Navin Cooray and MSH's Dr Cullen O'Gorman are testing the feasibility of a smart footprint system for diabetes-related foot care.

Pictured Above: **Professor Rik Thompson (QUT).**

More Clinical Collaborations

TRI's Research and Clinical Translation Team facilitating new collaborations, flowing from presentations to Princess Alexandra Hospital (PAH) clinicians. Among the collaborations is one involving PAH Neurology Department epilepsy team working with Mater Research's Dr Carlie Cullen.

Support for TRI commercial tenant Microbio with clinical collaborations within a number of PAH departments. Microbio aims to conduct a clinical trial in 2024 to develop pathogen detection technology. TRI was instrumental in connecting the Microbio team with the PAH ICU, Emergency and the Infectious Disease Management departments.



Pictured Above, **Dr Lauren Aoude (UQ).**
Pictured Below, **LINC Grant Recipients.**

LINC Grants to tackle unmet medical need

Research projects in cancer, children's immunity and blood infection have been supported with funding from TRI and clinical partners Metro South Health (MSH) and Children's Health Queensland (CHQ). Seven projects secured support in the latest round of Leading Innovations through New Collaborations (LINC) grants, with each to receive $50,000 in seed funding.

Queensland Minister for Health, Mental Health and Ambulance Services, Shannon Fentiman, awarded the grants in December. The recipients are:

- **UQ's Dr Michelle Chamoun and MSH's Dr Burcu Isler for preventing blood stream Infection by removing E. coli's protective cloak**
- **UQ's Dr Ming Tang and MSH's Dr Samantha Ng to develop novel drugs for the prevention and treatment of skin cancer in immunosuppressed organ transplant recipients**
- **UQ's Dr Amelia Soderholm and MSH's Dr Catherine Barnett for a localised immune checkpoint therapy for cutaneous head and neck cancer**
- **UQ's Dr Lauren Aoude and MSH's Dr Adam Frankel for using patient-derived 3D mini organs, called organoids, to accelerate personalised treatment of oesophageal cancer**
- **UQ's Dr Yang Yang and MSH's Dr Rahul Ladwa for engineering personalised vaccines to prevent a skin cancer called cutaneous Squamous Cell Carcinoma**
- **UQ's Dr Tatiane Yanes and CHQ's Dr Peter McNaughton for research into the genomics of paediatric inborn errors of immunity**
- **UQ's Dr Joseph Yunis and CHQ's Shook Fe Yap for developing a personalised T cell vaccine for a type of tumour called Ewing Sarcoma.**

A supportive environment for researchers

TRI offers an ecosystem that not only provides facilities and services, but also training and support for upskilling researchers to successfully communicate, collaborate, translate and commercialise. The suite of initiatives encompasses skills training sessions, mentoring programs and financial support for collaborative research projects.

Supporting translation

TRI held its fourth annual **Translation Pathways Program** training workshop, providing researchers and clinician-researchers with a better understanding of the translational pathways available for research. Key topics included understanding the wider research ecosystem, evaluating a project's translational potential, engaging with stakeholders and crafting a stakeholder pitch. In the past four years, the program has delivered a 4526% return on investment in funding outcomes and has been transformative for many of the 142 EMCRs involved.

Through the Translation Pathways Program, TRI has launched **Translation Fellowships** to provide support and training for developing future research leaders. Four fellowships have been offered, valued at $20,000 each and covering one-on-one translation coaching, attending a training program and automatic acceptance into TRI Translational Pathways workshops. The recipients are QUT's Dr Sonia Henriques, UQ's Dr Ming Tang, Mater Research's Dr Ran Wang and Queensland Health's Dr Justyna Ostrowski.

More Collaborations

TRI's Research Translation Committee focused on connecting with the clinic and adopting digital technology as part of its seminar in June. Presenters included QUT Professor Rik Thompson, UQ Professor Ranjeny Thomas and Dr Tom Lynch from the Australian Arthritis and Autoimmune Biobank Collaborative, a national musculoskeletal and autoimmune disease biobanking network developing data collection, linkage, analytics and machine-learning capabilities for research discovery.

QUT's Dr Adrian Wiegmans has built a collaboration with TRI-based CARPE Vitae Pharmaceuticals, using a **Researcher Exchange and Development within Industry Fellowship** worth $10,000. TRI-based MTPConnect offers the fellowships to support companies to bring Australian academics, clinicians and professionals in-house for work on priority medical research projects.

TRI-based researchers partnering with UQ commercialisation company UniQuest have secured $2 million to establish two startup companies and progress two health security projects under the Medical Research Future Fund's Brandon BioCatalyst-run **CUREator** incubator. Brandon is a TRI commercial tenant. Micromune Therapeutics will develop a small molecule therapeutic for inflammatory bowel disease, building partly on research from Mater Research Associate Professor Jakob Begun. Sycura Therapeutics will evaluate a small molecule for amyotrophic lateral sclerosis, building partly on research from QUT Associate Professor Richard Gordon.

TRI-based researchers have taken part in the MTPConnect and QUT **Bridge Program**, offering training in the various disciplines that contribute to the commercialisation of new medicines. They included QUT's Dr Amila Suraweera and Dr Mark Adams as well as UQ's Dr Hanno Nel. Dr Adams leveraged his new-found skills to be named one of two winners of the Bridge Program Pitch Competition.

Clinician-Researcher Networking events, bringing TRI-based scientists together with clinicians to share knowledge and explore collaborations that enable advancements in areas such as paediatric oncology and infectious disease.

AusBiotech

TRI welcomed AusBiotech delegates from around the world to Brisbane in November and showcased our translational research, cutting-edge facilities and expertise, entrepreneurial mindsets, support of early-stage biotech companies, manufacturing capabilities and future focus.

We worked with collaborators, industry partners and TRI tenants to conduct tours for 100 delegates and had strong representation at AusBiotech at the Brisbane Convention and Exhibition Centre, with a presence for the duration of the event.

Emeritus Professor Ian Frazer from UQ and TRI-based company Microba delivered the prestigious AusBiotech Millis Oration, sharing predictions for Australian biotechnology and detailing challenges to developing treatments while building sovereign vaccine and drug manufacturing capabilities.

TRI used the occasion to sign a BioManufacturing Alliance Memorandum of Understanding, continuing collaboration with Cytiva, Thermo Fisher Scientific, UQ, QIMR Berghofer Medical Research Institute and Springfield City Group.

More Partnerships and Knowledge Sharing

Professor Frazer being appointed Queensland's Biomedical Advisor, responsible for promoting the State's biomedical sector and advocating for further investment in our biomedical ecosystem.

Then Queensland Deputy Premier Dr Steven Miles meeting a TRI delegation at BIO International Convention in Boston in the United States, and speaking to a global audience about Translational Manufacturing @TRI and the new Translational Science Hub.

TRI joining UQ, QIMR Berghofer Medical Research Institute, Life Sciences Queensland, Thermo Fisher Scientific, Cytiva and Springfield City Group in the BioManufacturing Alliance, bringing together capabilities across biotherapeutics and vaccines to develop biomanufacturing capability.

TRI becoming home to the Translational Science Hub, a collaboration between Sanofi, UQ, Griffith University and the Queensland Government to advance mRNA vaccine development and deliver 200 new highly-skilled science and research roles, along with increased pathways for young people into the biomedical sector.

TRI having representation in the Mental Health Collaborative Group, established through our partner Health Translation Queensland, aiming to provide better outcomes for Queenslanders experiencing mental health challenges.

TRI providing a platform for knowledge sharing, training and development, showcasing research and exploring collaboration through 79 TRI-hosted events, including workshops, seminars and conferences, as well as logistics and booking support provided to a further 258 events.

Enabling future leaders to build a solid career path

The TRI culture and in-house services set students and early-career researchers up for success through initiatives that support them to build networks, find mentors, travel and share their knowledge. Their successes include prestigious international scholarships, competitive Federal Government funding and national award recognition.

Pictured: **PhD candidate Melody Dobrinin (QUT).**

Fulbright Scholar investigates the secret life of a healthy gut

QUT PhD candidate Melody Dobrinin will spend 10 months at the University of Arizona, with support from a prestigious Fulbright Scholarship.

The 10 months in the US will enable Ms Dobrinin to develop new therapies for inflammatory bowel disease (IBD).

Her PhD studies for the QUT Centre for Microbiome Research, under the supervision of TRI-based Professor Gene Tyson, aim to determine how gut-friendly bacteria could be turned into probiotics to treat digestive disease.

Ms Dobrinin hopes her research will one day also benefit people with depression, obesity and diabetes – which are increasingly being linked to gut health.

Fulbright Australia promotes education and cultural exchanges between Australia and the US to enhance mutual understanding and strengthen relations between the two countries.

Support for PhD Candidates and Early-Career Researchers

- TRI's **EMCR Professional Development Workshop**, attracting 120 delegates and covering leadership, managing people and finances, career pathways and transitioning from PhD candidates to postdoctoral researchers.
- The monthly TRI **EMCR Networking Morning Tea** series, with speakers detailing topics such as access to research facilities and biobanks, research translation, applying for grants, publishing, presenting research outcomes and commercialisation.
- **TRI Foundation Travel Sponsorship Awards**, enabling a group of 10 PhD candidates and early-career researchers to travel nationally and internationally for activities that facilitate career development, such as presenting at conferences, networking and visit other research institutes. Recipients were UQ's Ana Maria Romero, Bhadra Varma, Clara Heider, Dr Lia Kim, Leslie Domínguez and Dr Tom Schultz, Mater Research's Cheng Foo and Haressh Sajiir, and QUT's Eamonn McKenna and Dr Mohanan Maharaj.

Mater Research's Dr Chloe Yap being highly commended in the Discovery Award category at the Research Australia Awards, recognising outstanding efforts and achievements in driving and supporting the opportunities that health and medical innovation bring to our lives.

Dr Yap being the lead author of a study involving more than 40 researchers, clinicians, the autism community and 765 child donors and publishing results in Nature Medicine. Considered a major shift in autism research, the study has found that fat molecules contribute to sleep disturbances in children with autism.

More Achievements from Future Leaders

The Australian Research Council awarding competitive Discovery Early Career Research Awards to TRI-based researchers. UQ's Dr Anthony Chen will study the role of a key messenger protein in preventing immune cell exhaustion. QUT's Dr Nathalie Bock will study bone development.

UQ immunotherapy researcher Dr Arutha Kulasinghe being named 2023 **Cure Cancer Researcher of the Year**, with QUT's lung cancer researcher Dr Mark Adams recognised as the runner-up.



UQ's Dr Emma Karlsen coming third from more than 100 people at science summit **Falling Walls** in Berlin, Germany, pitching her breast cancer therapeutic strategies to a global panel of experts.

Building Our Community

The inaugural ***One*TRI** Conference in October enabled the TRI community to better understand the research being undertaken here, share knowledge and grow partnering and collaborations.

The conference featured a showcase of translational research and presentations about careers, collaboration and TRI capabilities, with more than 300 participants, 39 speakers, 24 panelists and 14 poster presentations.

It provided an important opportunity for early and mid-career researchers to participate in the organisation, planning and active participation of the event.

“I have witnessed great collaboration and enthusiasm from committee volunteers who put together an exciting and diverse program,” TRI CEO Professor Scott Bell said.

Recipients of best presentation and poster awards included Mater Research’s Muhammed Sabdia, Selwin Samuel and Liam O’Brien, QUT’s Charles Bidgood and Dr Mark Adams, and TRI’s Dr Carina Walpole.

Event sponsors included Charles River, Evident (by Olympus), MTPConnect, Sanofi, Vaxxas, Tecniplast, PCI Pharma Services and Evolve Scientific.

Involving patients, consumers and the community in research

TRI is closely connected to the community that will benefit from the scientific advances being made here, through patient advocacy, study participation, donation of samples and charitable support. Researchers based at TRI take their ethical, regulatory, social and financial responsibilities seriously to safeguard participants, patient samples and philanthropic support.

Focusing on families to reduce skin cancer



Patients with a personal or family history have been undergoing genetic testing at Australia's first Familial Melanoma Clinic, as part of TRI-based Associate Professor Aideen McInerney-Leo's UQ research into management and prevention.

The clinic is at the Princess Alexandra Hospital and was officially launched in 2023.

TRI-based academic dermatologist Professor Peter Soyer from UQ leads the centre, offering total body Vectra 3D scans, dermascopic imaging of suspicious lesions and genetic testing.

The 3D imaging can track changes to people's skin over time. Associate Professor McInerney-Leo says 129 patients visited the clinic in 2023, enabling doctors to identify those at high risk, provide data for customised surveillance and improve long-term prognosis.

"We know that genetic testing improves screening and sun protective behaviours in patients. It also leads to better patient understanding of melanoma risks for themselves and their families," she says.

Associate Professor McInerney-Leo's research involves collaboration with consumer advocate Joy Leishman.

Support for Health Consumer Involvement:

Dialogue between researchers, clinicians and patients about empowering communities, engaging consumers, raising awareness and fostering collaboration at the UQ Frazer Institute's First Public Sarcoma Research Forum, held at TRI.

A grant and document review workshop at TRI, with 40 health consumers attending for discussions about upskilling, building confidence and working with researchers. TRI's Research and Clinical Translation Team designed the workshop in collaboration with facilitators and consumer advocates Anne McKenzie AM and Jessica Taylor.

An introduction to consumer and community involvement in health research, provided to 30 TRI-based researchers and clinician researchers from partner hospitals, as part of a Telethon Kids Institute workshop at TRI.

Consumers interacting with researchers at the third annual *One*TRI Breast Cancer Awareness Event, with presenters including QUT Professor Rik Thompson highlighting different research approaches.

Samples being taken from 37 patients as part of a UQ study that found skin with few visible freckles or blemishes may still carry sun-damaged DNA mutations that can trigger cancer.

Passe and Williams Foundation support for UQ's Dr Arutha Kulasinghe to develop a high-dimensional assessment of head and neck cancer, and for Dr Janin Chandra to restore immune cell function to increase responsiveness to targeted head and neck cancer immunotherapies.

QUT's Dr Laura Croft using tissue samples taken post-surgery from Princess Alexandra Hospital patients to create tumour organoids – 3D models of cancers to test a range of therapeutics and ultimately guide tailored treatments.

UQ's Dr Vanessa Bonazzi analysing more than 200 blood and tumour samples from 57 patients with oesophageal cancer to develop a blood test and ultimately improve survival rates.

Professor Josephine Forbes from Mater Research being involved in a study that has followed 1,500 families since 2013, collecting samples and surveys to determine why more children are diagnosed with Type 1 diabetes.

Mater Research Professor John Hooper collaborating with Mater oncologists to examine tumour specimens from more than 145 prostate cancer patients to improve treatment options.

Pictured: **Dr Joshua Tobin (Mater Research).**

Medical foundation and philanthropic support

- Mater Research's Dr Joshua Tobin receiving $US50,000 from the 2023 Conquer Cancer – AstraZeneca Young Investigator Award funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology; as well as $100,000 from Cancer Australia's Priority-driven Collaborative Cancer Research Scheme, funded by Cancer Australia and Can Too Foundation. This enables TRI-based Dr Tobin to investigate novel treatments for lymphoma.
- Mater Research Professor Brian Gabrielli being awarded a $500,486 grant from the Ovarian Cancer Research Foundation to study a potential tablet treatment that could be more effective and have fewer side effects than current chemotherapy.
- A $500,000 donation from The Lott by Golden Casket funding Mater Research geneticist Dr Sandy Richardson to study unexplained pregnancy loss and infertility in mothers. "We are hoping to provide a satisfying explanation for an increased proportion of pregnancy losses," Dr Richardson says.
- Mater Research Professor John Hooper receiving $300,000 from PanKind, the Australian Pancreatic Cancer Foundation, to investigate early detection and new treatments for pancreatic cancer.
- Professor Hooper also receiving a $100,000 Tour de Cure grant to study a fluorescent contrast agent which will potentially help surgeons better detect and excise ovarian cancers.
- QUT's Associate Professor Elizabeth Williams receiving a Tour de Cure Pioneering Research Grant, with matching funding from the PA Research Foundation, for developing new targets for treating prostate cancer bone metastases.
- QUT's Dr Amila Suraweera securing $74,000 in funding from International Lung Cancer Foundation in the US to develop a novel therapeutic for the treatment of non-small cell lung cancer.

Supporting our Next Generation

TRI is integral in forging collaborations, leading conversations and supporting programs that deliver on state and federal government initiatives for STEM promotion, workforce skilling and healthcare advocacy.

Students Performing Advanced Research - Queensland Education

TRI-based SPARQ-ed aims to leverage biomedical research education to foster students' aspirations as future global leaders, lower barriers to access, improve inclusivity, provide role models and change career trajectories.

SPARQ-ed welcomes students to its purpose-built education outreach space at TRI for immersion programs, engagement sessions and workshops covering topics such as cell biology and bacterial transformation.

Immersion programs involve students working on real biomedical research projects and using the latest technology to examine, test and analyse results and sharing findings with TRI-based researchers.

SPARQ-ed holds professional development workshops for teachers, demonstrating how the latest technologies are used in modern research and can be adapted to classroom activities.

The team also travels around Queensland to conduct hands-on workshops for school students and staff, providing skills and STEM knowledge and building strong connections with regional, rural and Indigenous communities.

SPARQ-ed is delivered through a collaboration between TRI and the Department of Education.

SPARQ-ed achievements

WORKSHOPS

2229 students participated

548 students from outside the Brisbane metropolitan area

4 workshops for low SES schools and for Aboriginal and Torres Strait students in Science Week

60 STEM Girl Power students hosted.

SENIOR RESEARCH IMMERSION SESSIONS

120 students participated

100% alumni respondents entered into university in 2024

5 alumni awarded Peter Doherty Awards for Excellence in STEM Education.

SCHOOL AND COMMUNITY ENGAGEMENT

5 professional development workshops for teachers and science technicians

14 community events

42 regional and remote students awarded Lions Medical Research Foundation scholarships for travel and accommodation to attend SPARQ-ed at TRI.

TRI Leadership

TRI Board

The TRI Board has responsibility for governance, developing our strategic direction, ensuring accountability, setting goals, and guiding the institute's culture and values. Board members have oversight of key policies, financial operations, risk management and compliance. They collectively provide leadership and guidance on TRI management.

Board members:

Emeritus Professor David Siddle
Independent Director

Professor Aidan Byrne
The University of Queensland

Dr Erin Rayment
QUT

Colleen Jen
Queensland Health

Jim Walker AM
Mater Research

Shared Leadership Committee

The Shared Leadership Committee is chaired by the TRI CEO and is comprised of the most senior member of each of TRI's partners. The SLC is a source of advice to the TRI CEO; a forum for planning collaborative activities; and, in some cases, a decision-making body, except for those matters that are the responsibility of the ELT.

SLC members:

- **Professor Maher Gandhi,** Mater Research
- **Professor John Upham,** Metro South Research
- **Distinguished Professor Patsy Yates AM**, QUT
- **Professor Paul Clarke,** UQ

TRI Foundation

The TRI Foundation seeks to develop sponsorship programs, internships, scholarships, fundraising events and commercial partnerships to support medical research at TRI.

Board members:

Emeritus Professor Ian Frazer
AC Board Chair

Dominic McGann
Board Director

Craig Casagrande
Board Director

Vale Chuck Feeney

We would like to pay tribute to philanthropist Charles 'Chuck' Feeney, who was instrumental in supporting the establishment of major research institutes around South-East Queensland – including TRI.

Mr Feeney and his wife Helga donated more than $8 billion through The Atlantic Philanthropies to causes around the world as part of their 'Giving While Living' philosophy, with $549 million donated to Australian research institutions.

More than $350 million was donated to Queensland and the $50 million gifted to help establish TRI at that time represented the largest sum from a non-government source to a single Australian medical research institute.

Mr Feeney refused to have his name on any of the approximately 200 buildings his foundation helped to fund. He was named a Queensland Great in 2019.

Mr Feeney died peacefully in San Francisco on October 9, 2023. He was 92.

Executive Leadership Team

TRI's Executive Team provides operational leadership, research support and organisational culture in areas that include finance, legal services, human resources, communications and marketing, facilities management, compliance and workplace health and safety.

Professor Scott Bell
Chief Executive Officer

Associate Professor Helen Benham, Executive Director of Translation

Karen Murphy
Chief Operating Officer

Kirsten Kiel-Chisholm
General Counsel and Company Secretary

Michelle Richards
Executive Director, Innovation and Commercial Partnerships

Melissa Watter
Director, Corporate Affairs and Marketing

Simon Preston
Director, Finance

Raj Davio
Director, ICT

2023 TRI Partner Group Leaders

Mater Research

TITLE	FIRST NAME	SURNAME	POSITION
Associate Professor	Jakob (Jake)	Begun	Group Leader, Inflammatory Bowel Diseases Research Director, Gastroenterology, Mater Hospital
Associate Professor	Lucy	Burr	Program Leader, Chronic and Integrated Care Group Leader, Respiratory and Infectious Diseases Research
Professor	Vicki	Clifton	NHMRC Senior Research Fellow Group Leader, Pregnancy and Development
Dr	Carlie	Cullen	Group Leader, Glial Neurobiology, Cognition and Behaviour Research
Associate Professor	Paul	Dawson	Group Leader, Neurodevelopmental Research Director, Higher Degree Research, MRI-UQ and Mater Clinical Unit Mater Foundation Principal Research Fellow
Professor	Simon	Denny	Program Leader, Healthcare Delivery and Innovation Group Leader, Mater Young Adult Research Director, Mater Young Adult Health Centre
Associate Professor	Adam	Ewing	Program Leader, Cancer Senior Research Fellow Group Leader, Translational Bioinformatics
Professor	Geoff	Faulkner	Program Leader, Neuroscience Group Leader, Genome Plasticity and Disease Group Leader, Genome Plasticity and Disease Professor in Neuroscience, Queensland Brain Institute and Mater Research
Professor	Vicki	Flenady	Program Leader, Mother and Baby Director, Stillbirth Centre of Research Excellence
Professor	Josephine	Forbes	Program Leader, Chronic and Integrated Care Group Leader, Glycation and Diabetes Complication Research
Dr	Cathy	Franklin	Program Leader, Neuroscience Group Leader, Queensland Centre for Intellectual and Developmental Disability
Professor	Brian	Gabrielli	Group Leader, Smiling for Smiddy Cell Cycle Research Professorial Research Fellow
Professor	Maher	Gandhi	Executive Director, Mater Research Director, Clinical Research Director, Mater Research Institute-The University of Queensland Group Leader, Blood Cancer Research Pre-eminent Senior Staff Haematologist, Princess Alexandra Hospital
Professor	Phillip	Good	Program Leader, Cancer Director, Mater Hospital Cancer Services
Professor	Jake	Gratten	Group Leader, Cognitive Health Genomics Principal Research Fellow
Professor	Janet	Hardy	Group Leader, Palliative Care Research
Associate Professor	Sumaira	Hasnain	Group Leader, Immunopathology Research NHMRC Career Development Fellow and Senior Research Fellow
Professor	John	Hooper	Group Leader, Cancer Cell Biology Research Mater Foundation Fellow and Senior Research Fellow
Professor	David	Hume	Group Co-leader, Macrophage Biology Research Professorial Research Fellow
Associate Professor	Katharine	Irvine	Group Leader, Innate Immunity and Inflammation Research
Dr	Dhanisha	Jhaveri	Group Leader, Neural Stem Cell Biology Research Senior Research Fellow, Mater Research and Queensland Brain Institute
Dr	John	Kemp	Group Leader, Musculoskeletal Genomics Research
Professor	Kum Kum	Khanna	Group Leader, Tumour Biology and Therapeutics Research
Professor	Sailesh	Kumar	Group Leader, Genesis Maternal Fetal Medicine Research
Associate Professor	Liisa	Laakso	Group Leader, Allied Health Research
Professor	Jean-Pierre	Levesque	Group Leader, Stem Cell Biology Research
Professor	Helen	Liley	Program Leader, Mother ad Baby Group Leader, Critical Care of at Risk Newborns Research
Professor	Aileen	McGonigal	Group Leader, Mater Epilepsy Unit Research
Professor	Peter	Nestor	Group Leader, Cognitive Neurology
Professor	Allison	Pettit	Director, Biomedical Research Group Leader, Bones and Immunology Professor of Medicine
Professor	Kristen	Radford	Group Leader, Cancer Immunotherapies Research Principal Research Fellow
Associate Professor	Kym	Rae	Group Leader, Indigenous Health Research
Dr	Sandra (Sandy)	Richardson	Group Leader, Developmental Molecular Genetics
Professor	Katharina	Ronacher	Group Leader, Infection, Immunity and Metabolism Research Principal Research Fellow
Professor	Kim	Summers	Group Leader, Genetics, Genomics and Transcriptomics Research Professorial Research Fellow
Dr	Andrew	Swayne	Neuroimmunology Research
Associate Professor	Ingrid	Winkler	Group Leader, Stem Cells and Cancer Senior Research Fellow

Queensland University of Technology

TITLE	FIRST NAME	SURNAME	POSITION
Dr	Mark	Adams	Senior Research Fellow Team Leader within the Cancer and Ageing Research Program
Professor	Selena	Bartlett	Professor of Neuroscience Group Leader, Neuroplasticity, Addiction and Neuroscience / Psychology
Professor	Jyotsna	Batra	Advance Queensland Fellow Group Leader within APCRC-Q
Dr	Nathalie	Bock	Senior Research Fellow Deputy Co-Director, Regenerative Medicine Program Group Leader, Bone and Tumour Bioengineering Research
Dr	Emma	Bolderson	Senior Research Fellow Team Leader, Molecular Biology of Ageing Laboratory Co-founder, Carpe Vitae Pharmaceuticals
Professor	Lisa	Chopin	Group Leader, Gherlin Research
Distinguished Professor	Judith	Clements	Member, APCRC-Q
Dr	Laura	Croft	Advance Queensland Industry Research Fellow Team Leader within the Cancer and Ageing Research Program
Associate Professor	Richard	Gordon	Group Leader, Translational Neuroscience & CNS Therapeutics
Dr	Jennifer	Gunter	Senior Research Fellow Group Leader, Cancer Metabolism within APCRC-Q
Dr	Sonia	Henriques	Senior Lecturer Group Leader, Peptide Therapeutics and Membrane Biology
Dr	Brett	Hollier	Senior Research Fellow Group Leader, Invasion and Metastasis Laboratory, within APCRC-Q
Associate Professor	Alex	Lehn	Clinical Associate Professor, Translational Neuroscience & CNS Therapeutics
Associate Professor	Paul	Leo	Principal Research Fellow Senior Bioinformatician, Australian Translational Genomics Centre
Dr	Jacqui	McGovern	Senior Research Fellow Team Leader with Regenerative Medicine Group
Associate Professor	Simon	McIlroy	ARC Future Fellow Team Leader within the Centre for Microbiome Research
Professor	Colleen	Nelson	Executive Director, APCRC-Q
Professor	Kenneth (Ken)	O'Byrne	Professor, Medical Oncology Clinical Lead, Cancer and Ageing Research Program Clinical Director, Australian Translational Genomics Centre Consultant Medical Oncologist, Metro South Health
Dr	Lisa	Philp	Advance Queensland Industry Research Fellow – Mid Career Group Leader, Translational Adipokine Group within APCRC-Q
Associate Professor	Pamela	Pollock	Principal Research Fellow Group Leader, Endometrial Cancer
Professor	Derek	Richard	Chenhall Research Scientist and Principal Research Fellow Scientific Director, Cancer and Ageing Research Program Director, Queensland Centre for Drug Discovery
Dr	Aaron	Smith	Senior Lecturer Group Leader, Melanoma Group
Associate Professor	Sally-Anne	Stephenson	Group Leader, Protein Ablation Cancer Therapeutics Group (PACT)
Dr	Nataly	Stylianou	Research Fellow Team leader with APCRC-Q
Professor	Erik (Rik)	Thompson	Professor of Breast Cancer Research Group Leader, Invasion and Metastasis Unit
Professor	Gene	Tyson	Professor of Microbial Genomics ARC Future Fellow Director, Centre for Microbiome Research Co-founder, Non-Executive Director, Microba Life Sciences
Associate Professor	Ian	Vela	Lead Clinician, Queensland Bladder Cancer Initiative Urologic Oncologist, Princess Alexandra Hospital Urologic Oncologist, Urocology
Associate Professor	Elizabeth	Williams	Head, Tumour Models Group Leader, Queensland Bladder Cancer Initiative
Associate Professor	Ben	Woodcraft	Principal Research Fellow Team Leader within the Centre for Microbiome Research

University of Queensland

TITLE	FIRST NAME	SURNAME	POSITION
Professor	Andrew	Barbour	Professor, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine
Professor	Gabrielle	Belz	Chair in Immunology, Frazer Institute, Faculty of Medicine
Professor	Antje	Blumenthal	Professor, Frazer Institute, Faculty of Medicine
Associate Professor	Andrew	Brooks	Principal Research Fellow, Frazer Institute Faculty of Medicine
Dr	Janin	Chandra	Senior Research Fellow, Frazer Institute Faculty of Medicine
Dr	Zhian	Chen	Senior Research Fellow, Frazer Institute Faculty of Medicine
Emeritus Professor	Ian	Frazer	Emeritus Professor, Faculty of Medicine
Dr	Jazmina	Gonzalez Cruz	Senior Research Fellow, Frazer Institute Faculty of Medicine
Associate Professor	Fernando	Guimaraes	Principal Research Fellow, Frazer Institute. Affiliate Senior Research Fellow, School of Biomedical Sciences
Professor	Nikolas	Haass	Professor, Frazer Institute, Director (Research Training), Research Strategy and Support (Medicine), Faculty of Medicine
Associate Professor	Emma	Hamilton-Williams	Principal Research Fellow
Dr	Mathew	Jones	Senior Lecturer, School of Chemistry and Molecular Biosciences, Faculty of Science. Senior Research Fellow, Frazer Institute, Faculty of Medicine

University of Queensland Continued

TITLE	FIRST NAME	SURNAME	POSITION
Dr	Colm	Keane	Principal Research Fellow, Frazer Institute, Faculty of Medicine
Professor	Kiarash	Khosrotehrani	Professor, Frazer Institute, Faculty of Medicine
Dr	Arutha	Kulasinghe	Senior Research Fellow, Frazer Institute Faculty of Medicine
Dr	Snehlata	Kumari	Senior Research Fellow, Frazer Institute Faculty of Medicine
Associate Professor	Graham	Leggatt	Associate Professor in Immunology, Frazer Institute, Faculty of Medicine. Director (Research Training), Research Strategy and Support (Medicine), Faculty of Medicine
Associate Professor	Aideen	McInerney-Leo	Principal Research Fellow, Frazer Institute, Faculty of Medicine
Dr	Yousuf	Mohammed	Senior Research Fellow, Frazer Institute Faculty of Medicine
Professor	Mark	Morrison	Chair and Group Leader, Metagenomics, Frazer Institute, Faculty of Medicine
Emeritus Professor	Michael	Roberts	Emeritus Professor, Frazer Institute Faculty of Medicine
Associate Professor	Helmut	Schaider	Associate Professor, Dermatology, Frazer Institute, Faculty of Medicine. Course Coordinator, General Practice Clinical Unit, Faculty of Medicine
Associate Professor	Fiona	Simpson	Principal Research Fellow, Frazer Institute, Faculty of Medicine
Professor	Peter	Soyer	MRFF-NG Practitioner Fellow, Frazer Institute, Faculty of Medicine
Dr	Mitchell	Stark	Senior Research Fellow, Frazer Institute Faculty of Medicine. Course Coordinator, Skin Cancer, General Practice Clinical Unit, Faculty of Medicine
Associate Professor	Raymond	Steptoe	Associate Professor in Immunology, Frazer Institute, Faculty of Medicine. Director (Research Training), Research Strategy and Support (Medicine), Faculty of Medicine
Professor	Michael	Stowasser	Professorial Research Fellow, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine
Associate Professor	Rik	Sturm	Principal Research Fellow, Frazer Institute, Faculty of Medicine
Professor	Ranjeny	Thomas	Arthritis Queensland Chair of Rheumatology, Frazer Institute, Faculty of Medicine
Professor	Brandon	Wainwright	Professor, Frazer Institute, Faculty of Medicine
Associate Professor	James	Wells	Associate Professor, Frazer Institute, Faculty of Medicine
Dr	Timothy	Wells	Senior Research Fellow in HMR, Frazer Institute, Faculty of Medicine
Professor	Di	Yu	Chair in Paediatric Immunotherapy, Child Health Research Centre, Faculty of Medicine. Professorial Research Fellow, Frazer Institute Faculty of Medicine

Metro South Health Hospital & Health Services (& UQ)

TITLE	FIRST NAME	SURNAME	POSITION
Associate Professor	Stefan	Blum	Professor, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ. Staff Specialist, Neurology, PAH
Professor	Carmel	Hawley	Professor, Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, UQ. Senior Staff Specialist, Director Haemodialysis Services, PAH
Associate Professor	Ingrid	Hickman	Principal Research Fellow, UQ Centre for Clinical Research, Royal Brisbane and Women's Hospital, Herston, UQ
Professor	Gerald	Holtman	Director, Department of Gastroenterology and Hepatology, PAH. Director of Clinical Innovation (seconded), Faculty of Medicine, Herston Campus, UQ
Professor	David	Johnson	Director, Metro South and Ipswich Nephrology and Transplant Service. Medical Director, Queensland Renal Transplant Service, PAH. NHMRC Leadership Fellow, Centre for Health Services Research, PAH, UQ
Professor	Kenneth (Ken)	O'Byrne	Professor, Faculty of Health, QUT Staff Specialist, Oncology, Princess Alexandra Hospital. Honorary Professor, Frazer Institute, Faculty of Medicine, UQ
Professor	Ben	Panizza	Professor, PAH Southside, UQ. Staff Specialist, Ear, Nose and Throat, PAH
Professor	Elizabeth	Powell	Senior Staff Specialist, Department of Gastroenterology and Hepatology, PAH.
Professor	John	Upham	Professor of Respiratory Medicine, PAH Southside Clinical Unit, Faculty of Medicine, UQ. Director, Lung and Allergy Research Centre Executive Director, Metro South Health Research
Dr	Michael	Wagels	Staff Specialist Plastic and Reconstructive Surgeon and Deputy Director, Department of Plastic and Reconstructive Surgery, PAH. Director, ACCISS, TRI. Senior Lecturer, Royal Brisbane CU (Partners Royal Brisbane and Women's Hospital), Herston, UQ

Acronyms and Abbreviations

AAMRI	Association of Australian Medical Research Institutes
ACCISS	Australian Centre for Complex Integrated Surgical Solutions
AIBN	Australian Institute for Bioengineering and Nanotechnology
ARC	Australian Research Council
BRF	Biological Resources Facility
CAN	Clinical Alliance Network
CHO	Chief Health Officer
CHQ	Children's Health Queensland
CI	Co-investigator
CRC	Cooperative Research Centre
CRF	Clinical Research Facility
ELT	Executive Leadership Team
FDA	Food and Drug Administration
FTE	Full time equivalent
GMP	Good manufacturing practice
HR	Human resources
HTQ	Health Translation Queensland
ICT/IT	Information (and Communication) Technology
LINC	Leading Innovations through New Collaborations
LSQ	Life Sciences Queensland
MP	Member of Parliament
MR/MRI	Magnetic resonance (imaging)
MRFF	Medical Research Future Fund
MSH	Metro South Health
MTP	Medical technology, biotechnology and pharmaceutical
NHMRC	National Health and Medical Research Council
PAH	Princess Alexandra Hospital
PI	Principal investigator
QUT	Queensland University of Technology
RHO	Research House Officer
RNA	Ribonucleic acid
RTC	Research Translation Committee
SHAP	Sexual Harassment Awareness and Prevention Committee
SLC	Shared Leadership Committee
SOC	Shared Operations Committee
SPARQ-ed	Students Performing Advance Research Queensland
TM@TRI	Translational Manufacturing at TRI
TRI	Translational Research Institute
TRIC	TRI at Children's
UQ	The University of Queensland
UQCHR	University of Queensland Centre for Health Services Research
UQFI	The University of Queensland Frazer Institute
WHS	Workplace Health and Safety

TRI

TRANSLATIONAL RESEARCH INSTITUTE
AUSTRALIA

PARTNERS

The University Of Queensland
AUSTRALIA

QUT

mater
research

Queensland
Government

Queensland Health